State Street Holds 4.6% Of Vera Therapeutics As Drug Launch Costs Climb
Vera's first partial commercial quarter brought $10.3 million in drug sales and a wider net loss.
State Street reported a 4.6% passive stake in Vera Therapeutics, which develops treatments for serious immune-system diseases, in an SEC ownership filing Tuesday. The position totaled 3,301,893 shares as of September 30, while Vera's move into drug sales came with higher launch spending and a wider quarterly loss.
Shared Authority, No Control Campaign
State Street had shared authority to sell or otherwise dispose of all 3,301,893 shares. Its shared voting authority covered 3,148,448 shares, and it had no sole voting authority.
State Street certified that the shares were bought and held as part of its ordinary business activities, rather than for an effort to change or influence Vera's control. The disclosure describes a passive position, not a campaign to direct the company's decisions.
Sales Begin, Launch Spending Rises
Vera launched TRUTAKNA on July 7 following accelerated FDA approval. The drug produced $10.3 million in sales during its first partial commercial quarter, the company reported, with demand and inventory stocking contributing approximately equally.
That split matters to the initial sales reading: the revenue included both demand and the stocking of inventory for the launch.
Vera's third-quarter selling, general and administrative expenses rose to $61.4 million from $27.5 million a year earlier. The company attributed the increase to investment in the launch. Its quarterly net loss widened to $93.7 million from $80.3 million.
The commercial rollout sits within a broader kidney-disease development business. Vera's lead candidate, atacicept, is a protein treatment patients inject at home that blocks the immune-signaling molecules BAFF and APRIL. It has been studied in IgA nephropathy, an autoimmune kidney disease, and other autoimmune kidney diseases.
Vera also holds worldwide rights to MAU868, an antibody targeting BK virus infections in kidney transplant recipients, and VT-109, a preclinical inhibitor of BAFF and APRIL.
Vera submitted an application in October to move TRUTAKNA beyond accelerated approval. The company expects full FDA approval in mid-2027.
Sources
- SCHEDULE 13G — STATE STREET CORPORATION re: VERA THERAPEUTICS INC (VERA) — SEC EDGAR
- Vera Therapeutics, Inc. (VERA) stock price, news, quote and history - Yahoo Finance — Yahoo Finance
- Vera Therapeutics Inc (VERA) (Q3 2026) Earnings Call Highlights: TRUTAKNA Launch Off to a ... — Yahoo Finance
- Vera Therapeutics Announces Inducement Grants Under Nasdaq — globenewswire.com